Intrinsiqs

Is Climb Bio, Inc. overvalued?

Climb Bio, Inc. (CLYM) — key valuation metrics and fundamentals.

No verdict
Price
$10.36
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$608.5M
Dividend yield
0.0%
Return on equity
-30.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CLYM's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.